V132 Vaccine for Healthy Older Adults

This trial aims to test the safety and immune response of a new vaccine called V132 in healthy older adults. Researchers will compare different formulations of the V132 vaccine with existing vaccines to evaluate their effectiveness and the body's reaction. The trial consists of two parts: initially testing different doses and then expanding to include more participants. It suits healthy individuals who have not recently received certain pneumococcal vaccines or experienced related diseases. As a Phase 1 trial, the research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive this new vaccine.

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Earlier research on the V132 vaccine has examined its safety and effects on the immune system in healthy older adults. These studies test different versions of V132. Since this research is in the early stages, it primarily observes immediate reactions and any side effects, especially near the injection site.

For CAPVAXIVE and PREVNAR 20, more safety information is available. Extensive studies have shown these vaccines are generally well-tolerated. Most side effects, if they occur, are mild and may include a sore arm or a slight fever.

Researchers are excited about the V132 vaccine formulations because they offer a new approach to protecting healthy older adults from infectious diseases. Unlike standard vaccines like PREVNAR 20™, which target specific pathogens, the V132 formulations are being tested for their potential to provide broader immune responses. This could mean more comprehensive protection and possibly a longer-lasting immunity, which is particularly important for older adults whose immune systems may not respond as robustly to traditional vaccines. By exploring different formulations in the trial, researchers aim to identify the most effective dose to maximize these benefits.

Research has shown that the V132 vaccine is under development to protect older adults from pneumococcal disease. This trial will evaluate different formulations of the V132 vaccine. Existing vaccines like PCV13 have effectively reduced serious cases of this disease in older adults. Studies suggest that newer vaccines, such as CAPVAXIVE and PREVNAR 20, also lower the risk of pneumonia in older adults. These vaccines have proven safe and effective, supporting the potential success of the V132 vaccine formulations tested in this trial.⁶⁷⁸⁹¹⁰